CLINICAL TRIALS PROFILE FOR CHLORPROMAZINE
✉ Email this page to a colleague
All Clinical Trials for CHLORPROMAZINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00122278 ↗ | Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines | Completed | Montefiore Medical Center | Phase 3 | 2005-07-01 | Migraines are a specific type of headache that frequently recur and are very painful. Although there are many medications that are effective against migraines, none of these medications cure 100% of migraines. Another problem with migraines is that although many times they get better after intravenous (IV) treatment in the emergency room (ER), about 1/3 of the time migraines recur the next day. The purpose of this research project is to see if adding a medication called dexamethasone to standard ER therapy will help patients get better quicker and stay pain-free more often than if they receive placebo. |
| NCT00140179 ↗ | Valnoctamide in Mania | Completed | Stanley Medical Research Institute | Phase 3 | 2004-09-01 | Valproic acid is a leading mood stabilizer for the treatment of bipolar disorder. Its well-known teratogenicity limits its use in young women of childbearing age. According to toxicologic studies the teratogenicity of valproate stems from its free carboxylic group. Valnoctamide is an isomer and an analog of valpromide. Unlike valpromide, valnoctamide does not undergo a biotransformation to the corresponding free acid. It is also likely or at least possible that valnoctamide is anti-bipolar. In mice valnoctamide has been shown to be distinctly less teratogenic than valproate. An injection at day 8 of gestation produced only 1% exencephaly (as compared to 0-1% in control mice and 53% in valproate treated mice). The investigators are performing a double-blind controlled trial of valnoctamide as an anti-bipolar drug. If shown to be anti-bipolar, valnoctamide could be an important valproate substitute for young women with bipolar disorder who are at risk of pregnancy. Patients newly admitted to the Beersheva Mental Health Center may participate if they meet Diagnostic and Statistical Manual of Mental Disorders - 4th edition (DSM-IV) criteria for mania or schizoaffective disorder, manic type. Patients admitted to the study are treated with risperidone at doses of the physicians' discretion beginning with 2 mg daily on days 1 and 2. Valnoctamide or placebo is begun at doses of 600 mg per day (200 mg three times daily) and increased to 1200 mg (400 mg three times daily) after four days. Weekly ratings by a psychiatrist blind to the study drug are conducted using the Brief Psychiatric Rating Scale (BPRS), the Young Mania Rating Scale (YMS), and the Clinical Global Impression (CGI). Weekly blood is drawn for drug levels of valnoctamide to be measured by gas chromatography. Each patient receives valnoctamide or placebo for 5 weeks. Low teratogenic mood stabilizers are a high priority for current research. |
| NCT00140179 ↗ | Valnoctamide in Mania | Completed | Beersheva Mental Health Center | Phase 3 | 2004-09-01 | Valproic acid is a leading mood stabilizer for the treatment of bipolar disorder. Its well-known teratogenicity limits its use in young women of childbearing age. According to toxicologic studies the teratogenicity of valproate stems from its free carboxylic group. Valnoctamide is an isomer and an analog of valpromide. Unlike valpromide, valnoctamide does not undergo a biotransformation to the corresponding free acid. It is also likely or at least possible that valnoctamide is anti-bipolar. In mice valnoctamide has been shown to be distinctly less teratogenic than valproate. An injection at day 8 of gestation produced only 1% exencephaly (as compared to 0-1% in control mice and 53% in valproate treated mice). The investigators are performing a double-blind controlled trial of valnoctamide as an anti-bipolar drug. If shown to be anti-bipolar, valnoctamide could be an important valproate substitute for young women with bipolar disorder who are at risk of pregnancy. Patients newly admitted to the Beersheva Mental Health Center may participate if they meet Diagnostic and Statistical Manual of Mental Disorders - 4th edition (DSM-IV) criteria for mania or schizoaffective disorder, manic type. Patients admitted to the study are treated with risperidone at doses of the physicians' discretion beginning with 2 mg daily on days 1 and 2. Valnoctamide or placebo is begun at doses of 600 mg per day (200 mg three times daily) and increased to 1200 mg (400 mg three times daily) after four days. Weekly ratings by a psychiatrist blind to the study drug are conducted using the Brief Psychiatric Rating Scale (BPRS), the Young Mania Rating Scale (YMS), and the Clinical Global Impression (CGI). Weekly blood is drawn for drug levels of valnoctamide to be measured by gas chromatography. Each patient receives valnoctamide or placebo for 5 weeks. Low teratogenic mood stabilizers are a high priority for current research. |
| NCT00169039 ↗ | Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia | Terminated | Commonwealth Research Center, Massachusetts | Phase 4 | 1994-12-01 | This study will examine the physical response to clozapine or chlorpromazine in people with schizophrenia that has not improved with treatment. |
| NCT00169039 ↗ | Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia | Terminated | Dartmouth-Hitchcock Medical Center | Phase 4 | 1994-12-01 | This study will examine the physical response to clozapine or chlorpromazine in people with schizophrenia that has not improved with treatment. |
| NCT00169039 ↗ | Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia | Terminated | National Institute of Mental Health (NIMH) | Phase 4 | 1994-12-01 | This study will examine the physical response to clozapine or chlorpromazine in people with schizophrenia that has not improved with treatment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CHLORPROMAZINE
Condition Name
Clinical Trial Locations for CHLORPROMAZINE
Trials by Country
Clinical Trial Progress for CHLORPROMAZINE
Clinical Trial Phase
Clinical Trial Sponsors for CHLORPROMAZINE
Sponsor Name
